Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06127095 · ClinicalTrials.gov registry record
A Study to Assess New Participant's Perspectives Beyond Clinical Efficacy of Monoclonal Antibody-Based Relapsing Remitting Multiple Sclerosis (RRMS) Treatments
A clinical trial, sponsored by Biogen.
- Completed
- Registry status
- 474
- Enrollment target
NCT06127095 is a clinical trial that has completed, run by Biogen. The registered enrollment target is 474 participants.
The verdict
NCT06127095 has completed, sponsored by Biogen.
- COMPLETED
- Registry status
- 474 participants
- Enrollment target
Study Summary
The primary objective of the study is to understand what the added value of natalizumab (Tysabri®) treatment is from a participant's perspective at a given time, based on a one-shot survey. The secondary objectives of the study also aim to characterize the participant's decision-making process to get the treatment; the burden of treatment, characterization of the study population, assessment of the quality of life (QoL), and fatigue dimension.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 474 participants |
| Start Date | 2023-11-24 |
| Est. Completion | 2024-11-28 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06127095
The ClinicalTrials.gov registry entry for NCT06127095 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 474 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Biogen, which has 334 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 0 interventions.
NCT06127095 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT06127095 about?
NCT06127095 is a clinical study titled "A Study to Assess New Participant's Perspectives Beyond Clinical Efficacy of Monoclonal Antibody-Based Relapsing Remitting Multiple Sclerosis (RRMS) Treatments". The primary objective of the study is to understand what the added value of natalizumab (Tysabri®) treatment is from a participant's perspective at a given time, based on a one-shot survey. The secondary objectives of the study also aim to characterize the participant's decision-making process to ge...
What is the current status of trial NCT06127095?
This trial is currently completed. The enrollment target is 474 participants. The study started on 2023-11-24. Estimated completion is 2024-11-28.
Who is sponsoring clinical trial NCT06127095?
This trial is sponsored by Biogen, which has 334 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.